key: cord-0931172-2nkq3phl
authors: Naeije, Robert; Caravita, Sergio
title: CPET for Long COVID-19
date: 2022-02-28
journal: JACC Heart Fail
DOI: 10.1016/j.jchf.2022.01.008
sha: 4e4ad10433d525b8d29cf6345b7425897e360ab7
doc_id: 931172
cord_uid: 2nkq3phl

nan

Dr Bhatt has received honorarium from Sanofi Pasteur and is supported by the National Heart, Lung, and Blood Institute (NHLBI) T32 postdoctoral training grant T32HL094301. Dr Vaduganathan has received research grants from and/or serves on advisory boards for American Regent, Amgen, AstraZeneca, Baxter Healthcare, Bayer AG, Boehringer Ingelheim, Cytokinetics, Lexicon Pharmaceuticals, Pharmacosmos, Relypsa, Roche Diagnostics, and Sanofi; has participated in speaking engagements for Novartis and Roche Diagnostics; and participates on clinical trial committees for studies sponsored by Galmed, Novartis, Occlutech, and Impulse Dynamics. All other authors have reported that they have no relationships relevant to the contents of this paper to disclose. The authors attest they are in compliance with human studies committees and animal welfare regulations of the authors' institutions and Food and Drug Administration guidelines, including patient consent where appropriate. For more information, visit the Author Center. The authors have reported that they have no relationships relevant to the contents of this paper to disclose. The authors attest they are in compliance with human studies committees and animal welfare regulations of the authors' institutions and Food and Drug Administration guidelines, including patient consent where appropriate. For more information, visit the Author Center. 

We appreciate the comments from Drs Naeije and Caravita and the citation of their work which was not available at the time our report was written. 1 with disordered breathing. Deconditioning is generally not characterized by ventilatory changes. The mechanism underlying these ventilatory abnormalities remain unclear. Anxiety or psychological stress is one potential explanation for the hyperventilation, but altered chemosensitivity, lung thrombotic, or fibrotic changes are also possible. I think we can agree that more research is needed to clarify the significance of our findings and to help find an answer for those patients afflicted with long COVID-19 syndrome. 

Phenotyping long COVID

Use of cardiopulmonary stress testing for patients with unexplained dyspnea postcoronavirus disease

The authors have reported that they have no relationships relevant to the contents of this paper to disclose. The authors attest they are in compliance with human studies committees and animal welfare regulations of the authors' institutions and Food and Drug Administration guidelines, including patient consent where appropriate. For more information, visit the Author Center.